Stellular Bio

We aim to improve the lives of patients with ocular surface disease (OSD) with our pioneering platelet-derived regenerative biologic (PRB) therapy. PRB harnesses the same regenerative potential that underlies bespoke autologous treatments such as platelet-rich plasma (PRP) — but in the form of a mass-manufactured treatment that is standardized, off-the-shelf, and low enough cost to be able to reach all OSD patients. Stellular has proven the efficacy of PRB in animal models and has established scalable manufacturing methods that will enable clinical trials and commercial production. We are pursuing initial clinical proof of concept in Sjogren's syndrome-related dry eye and are poised to expand rapidly into the broader OSD market.